A single-center, retrospective study incidences of occult endocrinopathies in patients with cancer undergoing immunotherapy
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Lung cancer; Malignant melanoma; Urogenital cancer
- Focus Adverse reactions
- 16 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology